

# The Duties of Drug Regulatory Affairs in the Pharmaceutical Sector

Mayur Dandekar, Umesh Telrandhe, Prajakta Dandekar,  
Sakshi Mandhane, Renuka Tale

*Department of Pharmaceuticals, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DU), Wardha, Maharashtra, India*

## Abstract

A product's long-term performance in the healthcare system is a priority for the regulatory affair (RA) team of the pharmaceutical sector. To meet regulatory requirements while accelerating the development and distribution of safe and efficient medical products to people throughout the world, they provide strategic, tactical, and operational guidance and assistance. Creating and implementing a regulatory plan that ensures the drug research group's combined efforts result in a product that not only satisfies international regulators but also sets itself apart from the competition is the responsibility of RA. The goal of using Common Technical Documents is to significantly reduce the amount of time and money that business must spend assembling applications for worldwide registration. A controlling specialized is a person who attends as a liaison amid foreign government bodies and medicinal businesses. RA professionals ensure that pharmaceuticals are benign, effective, and of high quality. They also ensure that product information is accurate and appropriate. All of these efforts contribute to the protection of public health. This section covers the evolution of RA, their function in the pharmaceutical business, and their involvement in enforcing laws that support the sector's expansion.

**Key words:** Common technical document global regulatory agencies, Drug approval process, Regulatory affair experts, Regulatory agencies

## INTRODUCTION

The field of government affairs, sometimes referred to as regulatory affairs (RA), deals with jobs in regulated industries such as banking, energy, pharmaceuticals, and health care. Regulatory issues have very specific connotations in the pharmaceutical, medical device, biological, and functional food sectors. The majority of businesses, from cutting-edge small biotech startups to enormous multinational pharmaceutical conglomerates, are governed by specific regulatory bodies. A century ago, this was not the case; today, blood and its derivatives are subject to stringent GMP, along with the supervised production of conventional herbal medicines, cosmetics, food, and diet products.<sup>[1]</sup> The current clearly defined, strictly regulated management system is the end result of dealing with the unique conditions of each regulatory regime. Accordingly, the more scientifically accurate the product, the more likely it is to be released on schedule. In Figure 1 shows various

departments of regulatory affairs in the pharmaceutical industry for regulating all departments.<sup>[2]</sup>

## HISTORY OF RA

In the 19<sup>th</sup> century, RA evolved as industry raised worries about the quality safety of products. The previously Pure Food and Drugs Act of 1906 and other groundbreaking consumer protection laws were created in the US in an effort to address these issues and signal the establishment of regulatory oversight. Regulatory bodies were established at the beginning of the twentieth century to monitor specific

### Address for correspondence:

Mayur Dandekar, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DU), Sawangi (Meghe), Wardha - 442001, Maharashtra, India. Phone: +91-8605962737. E-mail: mayurdandekar1727@gmail.com

**Received:** 05-04-2024

**Revised:** 06-11-2024

**Accepted:** 22-11-2024



**Figure 1:** Department of regulatory affairs

industries and safeguard the public's health and safety. Industries had to navigate numerous sets of regulations from various nations as global trade increased. Global regulatory standards were intended to be streamlined through international harmonization initiatives, such as the 1990 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).<sup>[3]</sup> Managing intricate international supply chains, adjusting to advancements in digital health, and handling fresh regulatory issues are among the difficulties.<sup>[4]</sup>

## USE OF RA IN THE PHARMACEUTICAL INDUSTRY

RA specialists work in tandem with marketers and research and development (R&D) to develop innovative solutions that use technological and regulatory developments to shorten time to market. Small time-to-market gains build up to big, real rewards in the shape of sales and profit, and new products ought to dramatically improve the company's bottom line. Novel approaches to clinical trial conduct, expedited regulatory clearance, and mitigation of process risks can all contribute to the expeditious development of novel pharmaceuticals while mitigating expensive miscalculations and measurement errors.<sup>[5]</sup>

### Varying international regulatory organizations

By offering creative and strategic help to R&D, Production, and Quality Control areas, among others, from the outset of a product's life cycle, RA specialists significantly enhance

the financial viability of an organization's development strategy and organization. A new pharmaceutical medication might take as long as 15 years for research and development and launch. In the interim, issues may come up through the scientific research stage and as a result of changing legislative frameworks. Regulatory experts assist the business in avoiding problems caused by flawed scientific reasoning, a lackluster presentation of facts, or superfluous paperwork.

### Matters of regulation role of professionals in industry

Academic institutions, the commercial sector, and the government all employ RA specialists. Experts in regulatory matters abound in these domains:

- Medication
- Medical equipment, examples from the industry include *in vitro* diagnostics
- Biotechnology and biologics
- Nutritional supplements
- Cosmetics.

### An overview of RA history

Regulations controlling the quality, safety, and efficacy of pharmaceuticals have been increased as a result of several tragedies that happened in the 1950s, including the thalidomide, vaccination, and sulfanilamide elixir disasters. The criterion for good manufacturing practices (GMPs) and Marketing Authorization (MA) has gradually increased as a result.<sup>[6]</sup>

### Pharmaceutical RA

If there are changes to the pharmaceutical manufacturing process, RA must understand them, assess them, and choose when and if to report the FDA even if the changes have nothing to do with dums. RA is a relatively new field that was born out of government efforts to protect public health and safety through product safety and efficacy monitoring in industries such as medication, animals drugs, medical devices, chemical pesticides, agrochemicals, beauty products, and alternative and complementary therapies. Enterprises engaged in the creation, examination, production, and dissemination of these commodities also wish to guarantee that the goods they market are secure and promote health preservation. Because they have a deep grasp of the rules and regulations, specialists in regulations and standards are frequently asked for guidance on these topics.<sup>[7]</sup>

### The significance of regulations

It is imperative to reduce a product's time to market to boost an organization's profitability in the present business environment. Either scenario could lead to a loss of millions of dollars in sales as well as a deterioration in the confidence

of investors, medical professionals, and patients. Often, the company's main point of contact with government representatives is the Regulatory Division.

### Management of products and RA

Beyond product registration, a key duty of a RA specialist is to provide high-level organizations with technical and strategic advice. Their counsel at all levels saves industries a significant deal of money and time when it comes to the legal and technological requirements involved in the process of developing and selling a product. Nations without independent laws recognize the commerce regulations between states and the health standards issued by the World Health Organization.<sup>[8]</sup>

### Development and research on regulatory aspects

To create innovative goods that take use of technology and regulatory developments to save marketing time, RA specialists work in tandem with marketing and research and development. While little time-to-market advantages convert into significant matter revenue gains, new goods are predicted to have a significant beneficial influence on the bottom lines of the companies. Rapid regulatory authorization acquisition, adaptable clinical trial design, and procedural oblivion are all beneficial.

### Details on how RA function

RA professionals are required to suit business expectations as India's pharmaceutical sector expands rapidly and competes on a worldwide scale. Experts in regulatory relations function as an intermediary between foreign regulatory bodies and the pharmaceutical sector. They have to comprehend the laws, rules, policies, guidelines, and directives that are published by the regulatory authorities. To give students the most recent innovations that benefit industries, it is becoming more and more important to incorporate current pharmaceutical industry goals into pharmacy colleges' core curricula.<sup>[9]</sup>

### The expert in drug RA

Meticulous control throughout the whole process is essential to comply with regulatory standards and provide a positive assessment of the security, efficiency, and quality in the quickest possible period. The Drug RA (DRA) professional must be qualified for the role and possess both a strong scientific background and an in-depth knowledge of both domestic and international law. Some DRA professionals may concentrate on electronic data representation (electronic submissions) and physician-assisted death. Reviewing marketing materials, submitting formularies, introducing new goods, requesting DMFs, and carrying out quality assurance are among the other duties. Working with the Ministry of Health and the company is a big responsibility. In



**Figure 2:** Function of regulatory affairs

Figure 2 shows functions of regulatory affairs are conducting the Planning For Development, Writing and Reviewing and Gathering prevision, Management Of Submission, and Reviewing and Gathering.<sup>[10]</sup>

## REGULATORY AUTHORITY IN DIFFERENT COUNTRIES USA

In addition, the Public Health Service Act and related regulations – many of which have nothing to do with food or medicine – are enforced by the USFDA. Headquartered in White Oak, Maryland, is the USFDA. In addition, the organization has 13 laboratories and 223 field offices spread across all 50 states. The USFDA began opening offices abroad in 2008, with the UK, China, India, Chile, and Belgium among the nations. The safe use guidelines were also required by this law. This act was named the Prescription Amendment Act of 1951 (sometimes referred to as the Durham-Humphrey Amendment 1955). There were notable modifications after the Kefauver–Harris Drug Amendments of 1962. This aftermath is the result of the catastrophe of the Thalidomide in Western Europe. After these modifications, the FDA mandated more safety data to support the effectiveness of new medications and GMPs before MA Approval.<sup>[11-13]</sup>

## RESPONSIBILITY OF RA PROFESSIONAL'S

Monitoring the always changing legislation in each district where the corporation wants to distribute its products is the responsibility of the RA professional. They also preach about the limitations and restrictions that are both legal and rational, and they gather, examine, and assess the rational facts that their creative partners are generating.

- 1 Stay in contact with worldwide regulation, rules, and client rehearses
- 2 Stay current on an organization's product line
- 3 Ensure that products from a business comply with the most recent regulations

4. Figure out administrative procedure for all fitting administrative entries for homegrown, worldwide as well as contract projects
5. Arrange, prepare, and review all pertinent reports, such as dossiers, and deliver them to administrative professionals within the time frame specified in the association's creation
6. Monitor the progress of each enrolment accommodation
7. Keep track of the enrolment expense record, the supported applications file, the DMF accommodations, and further reports
8. Attend to questions as they arise and ensure that enrolment and authorization are approved on time
9. Discuss current administrative requirements with R&D, Pilot Plant, ADI, and RA. Inform personnel in groups.<sup>[14-16]</sup>

### Pharma administrative issues occupations

Professionals in the medicine administration issues field will be asked to do a variety of tasks, such as writing item names and patent data and staying up to date on the latest developments within the company. Since many companies in the drug sector are worldwide in scope, a subsequent language is often appealing due to its prior work experience in a clinical or pharma context.<sup>[17]</sup>

### Makes a good RA professional

Even while degrees in biotechnology are becoming more and more valuable, the majority of administrative specialists are graduates of a logical field, usually the biological sciences or pharmacy. Experts in administration should always exercise strong judgment when doing their duties. Important attributes include respectability and the ability to inspire confidence and trust.<sup>[18]</sup>

## REQUIREMENTS FOR RA IN PHARMACY EDUCATION

Drug biotechnology and novel clinical device firms are among the best managed in the country. The medical sector in India is expanding quickly, and in order to meet the current demands of enterprises and remain competitive on a worldwide scale, administrative task professionals are required. Administrative endeavors experts serve as the liaison between general administrative agencies and pharmaceutical corporations. It is anticipated that they possess an understanding of the policies, procedures, directives, and policies of the administrative bodies. To provide the understudies with the most advanced skills to support the enterprises, there is an increasing necessity to integrate the present requirements of drug ventures into the standard educational plan of drug store schools. For now, this article looks at administrative education, its need,

available courses, learning resources, course content, and open opportunities in administrative affairs. In Table 1, describe above regulatory affairs work in the pharma sector for the regulated whole process.

### The organizational framework of RA

- Regulatory Strategy: Organizing regulatory matters
- The dynamic and ever-changing planning process for addressing important development challenges
- A strategy for product registration in international markets
- Arrange the distribution of labor, expenses, and time. Anticipations for the RA Organizations
- To guarantee that a dossier produces a SmPC that generates revenue
- To guarantee that the first customers who support the product are the regulators
- Information about regulations and networking.<sup>[19]</sup>

## LEGISLATIVE HISTORY OF DRUG REGULATION IN INDIA

A substantial body of legislation governing the efficacy, safety, and quality of pharmaceutical products was developed as a result of the 1950s thalidomide, immunization, and sulfanilamide elixir catastrophes. Consequently, MA and

**Table 1: Key aspect of regulatory affair**

S. No.	Aspect	Description
1.	Definition	The field that deals with regulations and compliance in industries such as pharmaceuticals, medical devices, food, and more.
2.	Regulatory Agencies	Government bodies (e.g. FDA, EMA, FDA, MHRA) responsible for creating and enforcing regulations
3.	Regulatory	Ensuring that products, processes, and operations meet all applicable regulatory requirements
4.	Product Approvals	The process of obtaining regulatory approval for products before they can be marketed or sold
5.	Regulatory Submissions	Compiling and submitting documentation to regulatory agencies for approval, including New Drug Applications (NDAs) and 51003 submissions
6.	Clinical Trials	Conducting studies to demonstrate the safety and efficacy of drugs and medical devices in humans

GMP standards are tightened. India had a comparatively pre-industrialized pharmaceutical industry till the 20<sup>th</sup> century.

### 1900–1960

To keep an eye on and regulate the widely accessible, low-cost drugs, the government created the Poisons Act of 1919. The sale or controlled possession of drugs that have been expressly labeled as poison is made easier by this act. It also detailed how the poisons were to be sold and kept safe, as well as how they should be packaged and labeled, how much might be sold at a time, and how the poisons the seller sold should be inspected and tested annually.<sup>[11]</sup> The manufacture, distribution, importation, and sale for Allopathic, Homoeopathic, Unani, and Siddha medications are regulated under the Drugs and Cosmetics Act, 1940.<sup>[12]</sup> India's laws governing drug advertising are enacted in the 1955 Drugs and Magic Remedies (Objectionable Advertisements) Rule. The highest possible selling price for both composition and bulk pharmaceuticals may be evaluated and set by the government under this rule.

### 1960–1970

There was little competition from Indian producers, and multinational corporations held a sizable share of the market due to the underdevelopment of the Indian pharmaceutical industry. Pure technological advancement was not given much priority as there was inadequate patent protection. The majority of drug shares are dependent on the huge import of medications, which results in low availability and expensive medicine prices.

### 1970–1980

The Indian Patents and Designs Act of 1911 was superseded on April 20, 1972, by the Indian Patent Act 1970, which established the legal framework for Indian patent protection. This act forbade the patenting of products, but it allowed the patenting of drug ingredient manufacturing processes and procedures. Drug price cap: The purpose of the Drug Prices Control Order (DPCC) was to protect customers from excessive prices.

### 1980–1990

The Indian industry made the necessary production facility establishments and investments in API process development between 1980 and 1990.

### 1990–2000

The home market has been growing rapidly in the pharmaceutical industry. The companies have started doing research and development.

### 2000–2010

We refer to this period of time as the Innovation and Research Period. During this period, creative research endeavors, the patenting of pharmaceutical formulations, procedures, and indications, as well as business mergers, were all started. Act on Patent Amendment, 2005: The Indian Patent (Amendment) Act, 2005 was introduced by the Indian government to address patent-related issues in the country, replacing the Patents (Amendment) Ordinance, 2004. To solve patent issues in the chemical, pharmaceutical, and technological sectors, the new Act fundamentally changed the legal structure governing patent protection. Required permits: Pharmaceutical items can be manufactured and exported “to any country with insufficient or no manufacturing capability for the said products.” These permits are available for both purposes.<sup>[20]</sup>

## RA PROFESSION

RA is a profession that emphasizes science, regulations, and business. Those in this field must be knowledgeable about changing legislation, industry practices, and technological advancements. They aid in the advancement and accessibility of safe and effective healthcare products, as well as spurring innovation across a variety of industries.<sup>[21]</sup>

### RA encompass all dynamics

- Multi-dimensional
- Science and technological knowledge
- Prolific communication skills
- Ability to work with individuals of different backgrounds, abilities, cultures, and personalities
- Getting input regarding process capabilities and product attribute specifications from different departments within the company.<sup>[22]</sup>

### RA in clinical trials

The company's primary point of contact for international regulatory bodies is the RA professional. These bodies include the US Food and Drug Administration (USFDA) as well as the Centre for Devices and Radiological Health; the UK's Medicines as well as Healthcare Products Regulatory Agency; the therapeutic Goods Administration; the European Medicines Agency at Australia; the Organization for Economic Collaboration as well as Development; as well as Health Canada. Receiving incentives or prizes from management for getting approvals quickly.<sup>[23-24]</sup>

### Parameter of RA

- Construction: Assembling and Submission Management
- Coordination: Writing, reviewing, and supervising

- Finding the Weaknesses through Testing
- Local legislation
- International guidelines (ICH) in addition to national and regional guidelines.<sup>[25,26]</sup>

### Emerging trends affecting regulatory strategy

- Regulatory agency collaboration
- Robust growth in emerging markets
- Acquisition and licensing opportunities
- Quality aspects throughout the entire supply chain
- ICH expansion.<sup>[27]</sup>

### Qualities and attributes needed to be a successful RA

- Have a positive impact on IT literacy
- Perform independently
- Convince accuracy
- Current caliber
- Powerful persistence and persuasion
- Technically sound knowledge.<sup>[28]</sup>

They play a significant role in the business and scientific success of the corporation.

## PRINCIPLE OF RA

### Purpose and of regulation

The preservation of public health is the primary goal of regulation. While this seems like a very straightforward objective, achieving it has necessitated the creation of numerous intricate laws. Some of the regulations may seem onerous and even oppressive to you as a novice on the subject. But as you read through this chapter, you'll see that a lot of the historic developments in the field of regulatory development were brought about by unfavorable events. As a result, you ought to acknowledge that the current rules are the condensed knowledge of prior experience.

The regulations rely on several fundamental ideas and concepts to accomplish their purpose.

- Safety
- Purpose
- Risk/benefit
- Quality.

The foundational idea behind every product is product safety. The product should ideally not cause any harm. Therefore, to comply with the requirements, the manufacturer or developer must take the necessary actions to guarantee and demonstrate the safety of the product that is being developed.<sup>[29]</sup>

Although they are not always effective, chemotherapy medications are known to induce serious adverse effects, such as extreme nausea and hair loss, in cancer patients. Even yet, because they can help treat a condition that might otherwise be fatal, they continue to play a crucial role in the fight against cancer.<sup>[30]</sup> Quality is the last topic that regulations cover. Safety and suitability for the intended use are two qualities you would identify with a high-quality product, as was previously said. Still, an excellent product would not be defined by these qualities alone. You also anticipate any good or service to be dependable and consistent in order for it to be deemed high-quality. Furthermore, when it comes to medical items, quality also refers to the necessity of proving compliance with established guidelines or relevant requirements for stability, purity, and content. Companies of this kind are legally obligated to implement a suitable quality control system, the details of which are primarily specified in legislation.<sup>[31]</sup>

### Recent developments

The European Union began to standardize the member states' laws governing healthcare products in 1980. In most member nations, the idea of regulating pharmaceuticals was well established and followed the US model, but many lacked meaningful medical device regulations. Meanwhile, the European Union was working on the idea of New Approach Directives, which would leave most technological details to comply with established standards (which are easier to update) and just include general principles in the legislation.

The New Approach Directive on medical devices was implemented by the Europeans, who took a risk and made the first significant conceptual change in healthcare regulation in almost a century. The European Model for medical device has largely been adopted by the Global Harmonization Task Force as the international template.<sup>[32]</sup>

### Future developments

Many in the RA sector anticipate that all healthcare items will ultimately adopt the new regulatory method since it provides the most effective means of bringing new medical innovations to market in a timely manner while ensuring acceptable safety. Businesses are creating more and more divisions dedicated to regulatory concerns. Some organizations may choose to contract out or outsource regulatory problems to outside service providers due to the always changing resources needed to fulfil regulatory standards. The department that is least affected by acquisitions, mergers, and recessions is RA, which is continuously developing and expanding. A uniform approach to regulatory filings and, consequently, their evaluation has resulted from the global harmonization of standards.<sup>[33]</sup>

## Regulatory scenario of herbal medicines

The definition of Ayurvedic, Siddha, and Unani (ASU) medicines was added to the scope of the pharmaceuticals and Cosmetics (Amendment) Act of 1964, together with all the required regulations for the control of this class of pharmaceuticals.<sup>[4,10]</sup> The law states that a license is needed to manufacture ASU pharmaceuticals, but it exempts them from sale as long as they are made under license. Appropriate labeling and packaging are also required for marketing these items, and GMP introduced Schedule T for ASU drug production facilities. Before herbal products can be approved in other countries, premarketing approval and proof of efficacy and safety are needed.<sup>[34]</sup>

## CONCLUSION

Many in the RA field believe that the new regulatory method will eventually be adopted for all healthcare products as it provides the best means of bringing new medical innovations to market quickly while maintaining acceptable levels of safety. RA is the department that is least impacted by mergers, acquisitions, and recessions since it is always evolving and growing. Businesses' RA departments are growing. Some organizations also choose to subcontract or outsource regulatory concerns to outside service providers due to the varying resources needed to fulfill regulatory duties. In the present competitive climate, a product's success and, by extension, the firm's success, depend on reducing the time it takes to reach the market. RA departments within their businesses. Thus, regulatory specialists are highly sought after. Since the industry is quite technical, pharmacy experts are once more qualified for these roles.

## REFERENCES

- Sutar MR, Gawhane DR, Tenpe CR. Study of drug regulatory approval process and comparative requirement of Common Technical Documents (CTD) in Europe, USA and India in coordination with drug developmental process. *Int J Pharm Sci Rev Res* 2013;20:68-79.
- Gopinath E, Bhadauria RS, Gunjan J, Insha Z. Pharmaceutical regulatory affairs - review. *Int J Adv Res Pharm Biosci* 2012;2:292-301.
- Sanghi DK, Tiwle R. Role of regulatory affairs in a pharmaceutical industry. *Int J Pharma Res Rev* 2014;4:127-31.
- Philip S, Philip A. The scope of regulatory affairs in the pharmaceutical industry. *Hygeia J Drugs Med* 2010;2:1-6.
- Sushma G, Debnath S, Santhosh Kumar C, Chandu AN. Quality and regulatory affairs of herbal drugs: A world-wide review. *Indo Am J Pharm Res* 2011;1:389-96.
- Sreedhar D, Subramanian G, Sreenivasa Reddy M, Udupa N. Need for the introduction of regulatory affairs in the pharmacy curriculum. *Health Adm* 2016;101:51-2.
- Kumar NK, Maheshwari D. Documentation requirements for generic drug application to be marketed in India- A review. *J Pharm Sci Biosci Res* 2014;4:237-42.
- Berger N. Rheumatoid arthritis medication adherence in a health system specialty pharmacy. *Am J Manag Care* 2020;26:e380-7.
- Yetter R, editor. Partnership in Harmonization. In: Proceedings of the Sixth International Conference on Harmonisation. Osaka, Japan; 2003.
- Borfitz D. Lifting India's barriers to clinical trials. *Center Watch* 2003;10:1-9.
- Regulatory Affairs Professional Society. Available from: <https://www.raps.org> [Last accessed on 2010 Mar 26].
- US Government Printing Office. Trials of War Criminals before Nuremberg Military Tribunals under Control Council Law No. 10. Vol. 2. Washington, DC: US Government Printing Office; 1949. p. 181-2.
- Williams JR. The declaration of Helsinki and public health. *Bull World Health Organ* 2008;86:650-1.
- The National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research. The Belmont Report, Office of the Secretary, Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: The National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research; 1979.
- World Health Organization. Guidelines for Good Clinical Practices (GCP) for Trials on Pharmaceutical Products. WHO Technical Report Series, No.850. Geneva, Switzerland: World Health Organization; 1995.
- Central Drugs Standard Control Organization. Good Clinical Practices for Clinical Research in India. New Delhi: Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; 2001.
- Dandekar M, Dandekar P, Mude S. The Impact of Healthcare Software in the Pharmaceutical Industry. In: 2024 International Conference on Innovations and Challenges in Emerging Technologies (ICICET). United States: IEEE; 2024. p. 1-5.
- Kumar BJ. Overview of drug regulatory affairs and regulatory profession. *Int J Drug Regul Aff* 2013;1:1-4.
- Gundersen LE. Training needs in regulatory science for the biopharmaceutical industry. *Nat Biotechnol* 2001;19:1187-8.
- Gundersen LE. Careers in regulatory affairs: From practitioner to professional. *Nat Biotechnol* 2001;20:409-10.
- Kumar S, Panwar R, Singh U. Regulatory affairs in the pharmacy curriculum. *Int J Res Dev Pharm Life Sci* 2013;2:690-8.
- Woodhouse D. Quality and quality assurance. Quality and Internationalisation in Higher Education. Paris: OECD; 1999.
- Elassy N. The concepts of quality, quality assurance and

- quality enhancement. *Qual Assur Educ* 2015;23:250-61.
24. Maggetti M. The role of independent regulatory agencies in policy-making: A comparative analysis. *J Eur Public Policy* 2009;16:450-70.
  25. Sai Hanuja G, Sai Kumari B, Nagabhushanam MV, Nagarjuna Reddy D, Bonthagarala B. Regulatory requirements for registration of generic drugs in “BRICS” countries. *Int J Pharm Sci Health Care* 2016;6:20-39.
  26. Sai Kumari B, Sai Hanuja G, Nagabhushanam MV, Nagarjuna Reddy D, Bonthagarala B. Current regulatory requirements for registration of medicines, compilation and submission of dossier in Australian therapeutic goods administration. *Int J Adv Sci Tech Res* 2016;6:144-57.
  27. Shakeel SM, Basha SS, Nagabhushanam MV, Nagarjuna Reddy D, Bonthagarala B. Comparison of regulatory requirements for generic drugs dossier submission in United States and Canada. *Int J Pharm Sci Health Care* 2016;6:1-19.
  28. Bonthagarala B. Nanomedicine clinical use, regulatory and toxicology issues in Europe. *J Drug Deliv Ther* 2019;9:846-8.
  29. Tamboli TH, Mane SR, Bais SK. Navigating compliance: The integral role of regulatory affairs in pharmaceutical industry. *Int J Pharm Herb Technol* 2024;2:2447-60.
  30. Chisholm O, Critchley H. Future directions in regulatory affairs. *Front Med (Lausanne)* 2023;9:1082384.
  31. Janjal VS, Dhamodkar SR, Jadhao YP, Manmode SB, Pawar AK, Khandelwal H. Recent drug regulatory affair and CTD module progress review for submission of pharmaceuticals product. *GSC Biol Pharm Sci* 2021;16:200-21.
  32. Telange DR, Patil AT, Pethe AM, Fegade H, Anand S, Dave VS. Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, *in vivo* bioavailability, and antioxidant potential. *Eur J Pharm Sci* 2017;108:36-49.
  33. Roshan K, Aayush, J. Role of regulatory affairs in pharmaceutical company: An overview. *Glob J Res Anal* 2015;7:51-3.
  34. Swetha Sri R, Mounika CH, Bhavya Sri K. A review on pharmaceutical regulatory agencies of India, USA and Europe. *Int J Res Trends Innov* 2020;5:134-43.

**Source of Support:** Nil. **Conflicts of Interest:** None declared.